KBR, Inc. KBR
Composite 51/100; the shares have moved about 36% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 27/100 — a moderate mark against it.
Valuation ranks 80/100 — a strong point in its favour. Income ranks 57/100 — a slight point in its favour. Growth ranks 52/100 — a slight point in its favour.
Momentum ranks 27/100 — a moderate mark against it. Balance-sheet strength ranks 42/100 — a slight mark against it. Quality ranks 46/100 — a slight mark against it.
What the company does KBR, Inc. provides scientific, technology, and engineering solutions to governments and commercial customers globally. Its segments include Government Solutions (defense, intelligence, space) and Sustainable Technology Solutions (ammonia/syngas, petrochemicals, decarbonization). The company also offers proprietary process technologies and high-end engineering services for energy transition and net-zero solutions.
Key financials KBR reports strong profitability metrics: ROE 29%, ROA 5%, ROCE 14%, and net margin 5%. Revenue and EPS growth are negative at -5% and -9%, respectively. Leverage is elevated (Debt/Equity 1.77, Net debt/EBITDA 3.70), though interest coverage stands at 4x. Valuation metrics include P/E 11x (forward 9x), EV/EBITDA 8x, and FCF yield 6%.
Stock health Momentum is weak: -4% over 3 months, -20% over 6 months, and -25% over 12 months, with RSI at 44. The Sideravia score (49/100) reflects average quality, attractive valuation, and weak momentum. Quality (54) and income (71) pillars are supportive, but growth (28) and momentum (24) lag.
Price vs fair value KBR trades at a PREMIUM of 0.30% to our fair-value estimate of 34.28 and at a discount of 33.42% to the analyst 12-month target of 45.86. - Q2 earnings topped estimates, but guidance sparked concerns about cash flow and the Trinzic spin-off (Simply Wall St., StockStory). - Analysts highlight a potential 25% rally based on Q2 beat (Zacks). - Recent headlines cite "obliterated" share performance post-earnings (StockStory).
Looking forward Forward P/E of 9x and PEG of 0.56 suggest undemanding valuation, but growth remains a concern. Management’s full-year guidance is optimistic, yet execution risks persist amid weak momentum and elevated leverage.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.